TRCT
TENX icon

Tower Research Capital (TRC)’s Tenax Therapeutics TENX Stock Holding History

Tower Research Capital (TRC)’s Portfolio TENX Stock Details TENX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.6K Buy
1,100
+901
+453% +$12.2K ﹤0.01% 3574
2025
Q4 		$2.43K Sell
199
-302
-60% -$2.63K ﹤0.01% 4529
2025
Q3 		$3.81K Sell
501
-748
-60% -$4.57K ﹤0.01% 4447
2025
Q2 		$7.19K Buy
1,249
+1,057
+551% +$6.11K ﹤0.01% 4069
2025
Q1 		$1.26K Buy
+192
New +$1.23K ﹤0.01% 4747
2024
Q4 		– Sell
-1,693
Closed -$5.86K – 6003
2024
Q3 		$5.86K Buy
1,693
+732
+76% +$2.65K ﹤0.01% 4209
2024
Q2 		$2.9K Buy
961
+424
+79% +$1.5K ﹤0.01% 4950
2024
Q1 		$2.28K Buy
537
+480
+842% +$3.68K ﹤0.01% 5081
2023
Q4 		$1.25K Sell
57
-1
-2% -$24 ﹤0.01% 5410
2023
Q3 		$1.39K Hold
58
– – ﹤0.01% 5345
2023
Q2 		$1.4K Sell
58
-8
-12% -$213 ﹤0.01% 5385
2023
Q1 		$2K Buy
66
+60
+1,000% +$6.26K ﹤0.01% 5403
2022
Q4 		$1K Hold
6
– – ﹤0.01% 5671
2022
Q3 		$2K Hold
6
– – ﹤0.01% 5617
2022
Q2 		$3K Buy
6
+3
+100% +$3K ﹤0.01% 5413
2022
Q1 		$4K Hold
3
– – ﹤0.01% 5253
2021
Q4 		$5K Buy
+3
New +$6.76K ﹤0.01% 5193
2021
Q3 		– Sell
-1
Closed -$2.62K – 6166
2021
Q2 		$3K Buy
+1
New +$3.17K ﹤0.01% 4960
2021
Q1 		– Sell
-11
Closed -$39.3K – 5218
2020
Q4 		$33K Buy
11
+8
+267% +$14.7K ﹤0.01% 3498
2020
Q3 		$8K Buy
+3
New +$6.4K ﹤0.01% 4195
2017
Q3 		– Hold
0
– -$10K – 4137
2017
Q2 		– Hold
0
– – – 1619
2016
Q3 		– Hold
0
– -$3K – 4427
2016
Q2 		– Hold
0
– – – 3743
2016
Q1 		– Hold
0
– – – 3166
2015
Q4 		– Hold
0
– – – 4161
2015
Q3 		– Hold
0
– – – 1586
2015
Q2 		– Hold
0
– – – 3796
2015
Q1 		– Hold
0
– – – 2304
2014
Q4 		– Hold
0
– – – 2925
2014
Q3 		– Hold
0
– – – 2905
2014
Q1 		– Sell
-1
Closed -$79K – 4914
2013
Q4 		$79K Buy
+1
New +$135K 0.01% 1000
2013
Q3 		– Hold
0
– -$1K – 4838
2013
Q2 		– Hold
0
– – – 3741

Other funds holding TENX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Tower Research Capital (TRC)'s TENX Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Tenax Therapeutics (TENX) stake by 453% in Q1 2026, buying an estimated $12.2K and bringing the position to 1,100 shares worth $17.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3574.

Tower Research Capital (TRC) first reported a position in TENX in Q4 2013 and has held it in 21 quarters since. The position peaked at $79K in Q4 2013. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

  • Tower Research Capital (TRC) held 1,100 shares of Tenax Therapeutics worth $17.6K as of Q1 2026.
  • Tower Research Capital (TRC) bought 901 Tenax Therapeutics shares in Q1 2026, an estimated $12.2K.
  • Tenax Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3574 holding.
  • Tower Research Capital (TRC) first reported a position in Tenax Therapeutics in Q4 2013 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Tenax Therapeutics position peaked at $79K in Q4 2013.
  • 80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.